Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:2697-2703
Published online before print November 3, 2003, doi: 10.1161/01.CIR.0000093279.36628.12
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/21/2697    most recent
01.CIR.0000093279.36628.12v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by André, P.
Right arrow Articles by Phillips, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by André, P.
Right arrow Articles by Phillips, D. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
*HEPARIN
Medline Plus Health Information
*Blood Thinners
Related Collections
Right arrow Arterial thrombosis

(Circulation. 2003;108:2697.)
© 2003 American Heart Association, Inc.


Basic Science Reports

Anticoagulants (Thrombin Inhibitors) and Aspirin Synergize With P2Y12 Receptor Antagonism in Thrombosis

Patrick André, PhD; Thomas LaRocca, BA; Suzanne M. Delaney, PhD; Pei Hua Lin, BS; Diana Vincent, BS; Uma Sinha, PhD; Pamela B. Conley, PhD; David R. Phillips, PhD

From Millennium Pharmaceuticals, Inc, South San Francisco, Calif.

Correspondence to David R. Phillips, Millennium Pharmaceuticals, Inc, 256 E Grand Ave, South San Francisco, CA 94080. E-mail david.r.phillips{at}mpi.com

Received December 16, 2002; de novo received June 6, 2003; revision received July 15, 2003; accepted July 15, 2003.

Background— This study was designed to determine whether (1) P2Y12 antagonism synergizes with other antithrombotics and (2) anticoagulants (thrombin inhibitors) affect the antithrombotic activity elicited by P2Y12 antagonism.

Methods and Results— Thrombosis was achieved by perfusion of human and murine blood through type III collagen–coated capillaries at arterial shear rate. CT50547, a direct-acting P2Y12 antagonist, inhibited thrombosis in PPACK- but not heparin-anticoagulated human blood. In contrast, CT50547 inhibited thrombosis in aspirin-treated individuals independently of the anticoagulant. Thrombin and TXA2 also synergized with P2Y12 in the absence of anticoagulation, because combined treatment of aspirin or C921-78 (a factor Xa inhibitor) with CT50547 or 2-MeSAMP (a P2Y12 antagonist) inhibited the thrombotic process, whereas all treatments failed to inhibit thrombosis when used individually. Synergism was also observed ex vivo when P2Y12-deficient (P2Y12-/-) mice were administered aspirin or coagulation inhibitors (C921-78 and bivalirudin). Finally, using intravital microscopy, we found that both C921-78 and bivalirudin abrogated the thrombotic process in P2Y12+/- mice, whereas each showed only partial efficacy in P2Y12+/+ animals.

Conclusions— Our study indicates that (1) thrombin inhibitors and aspirin have a demonstrable synergy of antithrombotic activity with P2Y12 antagonism and (2) the in vitro analysis of the antithrombotic activity of P2Y12 antagonists is affected by the anticoagulant used for blood collection. This suggests that the antithrombotic potential of P2Y12 antagonists in vitro may be overestimated in anticoagulated samples of blood and best achieved in vivo by the inclusion of aspirin and/or a thrombin inhibitor.


Key Words: anticoagulants • thrombosis • receptors, purinergic P2 • synergism




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Paniccia, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate, et al.
Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 734 - 739.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. V. Denis and D. D. Wagner
Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis
Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 728 - 739.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. W. Stone, B. T. McLaurin, D. A. Cox, M. E. Bertrand, A. M. Lincoff, J. W. Moses, H. D. White, S. J. Pocock, J. H. Ware, F. Feit, et al.
Bivalirudin for Patients with Acute Coronary Syndromes.
N. Engl. J. Med., November 23, 2006; 355(21): 2203 - 2216.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Aktas, M. Pozgajova, W. Bergmeier, S. Sunnarborg, S. Offermanns, D. Lee, D. D. Wagner, and B. Nieswandt
Aspirin Induces Platelet Receptor Shedding via ADAM17 (TACE)
J. Biol. Chem., December 2, 2005; 280(48): 39716 - 39722.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y. Wang, M. Sakuma, Z. Chen, V. Ustinov, C. Shi, K. Croce, A. C. Zago, J. Lopez, P. Andre, E. Plow, et al.
Leukocyte Engagement of Platelet Glycoprotein Ib{alpha} via the Integrin Mac-1 Is Critical for the Biological Response to Vascular Injury
Circulation, November 8, 2005; 112(19): 2993 - 3000.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Nanda, P. Andre, M. Bao, K. Clauser, F. Deguzman, D. Howie, P. B. Conley, C. Terhorst, and D. R. Phillips
Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling
Blood, November 1, 2005; 106(9): 3028 - 3034.
[Abstract] [Full Text] [PDF]